Clinical Risk Factors for Revisits for Children With Community-Acquired Pneumonia

Lilliam Ambroggio1,2,3, Helena Herman4, Emily Fain3,5

  • 1Divisions of Hospital Medicine, lilliam.ambroggio@cchmc.org.

Hospital Pediatrics
|October 25, 2018
PubMed

Insights

Children with community-acquired pneumonia (CAP) have a low revisit rate to the emergency department (ED). Receiving aminopenicillins during the initial visit was associated with a reduced likelihood of revisits.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Community-acquired pneumonia (CAP) is a common reason for pediatric emergency department (ED) visits.
  • Understanding factors associated with ED revisits in children with CAP is crucial for improving care and preventing readmissions.

Purpose of the Study:

  • To identify clinical factors associated with revisits to the emergency department (ED) within 30 days for children diagnosed with community-acquired pneumonia (CAP).

Main Methods:

  • A retrospective study analyzed 3304 pediatric ED visits for CAP between December 1, 2009, and April 31, 2013.
  • Multivariable logistic regression models assessed the association between clinical variables and ED revisits (primary outcome: CAP-related ED visit/hospitalization within 30 days; secondary outcome: CAP-related ED visit within 48 hours).

Main Results:

  • Of 3304 index visits, 148 (4.5%) resulted in an ED revisit.
  • Children with complex chronic conditions (CCCs) were 2.23 times more likely to revisit.
  • Children admitted to the hospital or treated with aminopenicillins during the index visit were less likely to revisit.

Conclusions:

  • While the overall revisit rate for pediatric CAP is low, specific factors influence readmission risk.
  • Aminopenicillin treatment during the initial ED visit was linked to a statistically significant reduction in revisits, even after accounting for disease severity markers.
Abstract

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.5K
What are Populations and Communities?00:30

What are Populations and Communities?

Overview
37.8K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
892
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.9K
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
815